CHICAGO, April 3, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today the presentation of two preclinical studies demonstrating compelling results for palifosfamide in breast cancer. The results were presented at the 2012 American Association for Cancer Research (AACR) Annual Meeting, being held March 31 – April 4 in Chicago, IL. Palifosfamide is currently being evaluated in a randomized, double-blinded, placebo-controlled Phase 3 trial (PICASSO 3) for the treatment of metastatic soft tissue sarcoma in the front-line setting.
